OpenClaim

Larotrectinib Side Effects

The most commonly reported side effects of larotrectinib include fatigue, dizziness, and death, based on 851 FDA adverse event reports from 2019 to 2025. 6.9% of reports found the drug to be ineffective.

#1 Reported: FatigueAll side effects ↓Top Co-Medication: EntrectinibDrug interactions ↓48% of Reports Are AdultDemographics ↓

Larotrectinib side effects

Percentages show how often each reaction appears relative to total reports for larotrectinib.

1
Fatigue7.2%61
2
Drug Ineffective6.9%59
3
Dizziness6.2%53
4
Death5.9%50
5
Neuropathy Peripheral5.1%43
6
Pain4.9%42
7
Nausea4.5%38
8
Off Label Use4.2%36
9
Disease Progression4.1%35
10
Myalgia3.1%26
11
Vomiting3.1%26
12
Malignant Neoplasm Progression2.7%23
13
Diarrhoea2.6%22
14
Rash2.5%21
15
Anaemia2.5%21

These are voluntary reports and do not establish that larotrectinib caused these reactions.

Report severity

73.9%Serious629 reports
19.2%Hospitalizations163 reports
18.4%Fatal157 reports

Seriousness is determined by the reporter, not by OpenClaim.

Larotrectinib drug interactions

Other drugs that appear in adverse event reports alongside larotrectinib. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Entrectinib2.1%18
2
Gemcitabine2.0%17
3
Carboplatin2.0%17
4
Etoposide1.6%14
5
Oxaliplatin1.5%13
6
Fluorouracil1.5%13
7
Levoleucovorin1.4%12
8
Paclitaxel1.3%11
9
Nivolumab1.2%10
10
Ipilimumab1.1%9
11
Doxorubicin-hydrochloride0.9%8
12
Cyclophosphamide0.8%7
13
Bevacizumab0.8%7
14
Vincristine-sulfate0.7%6
15
Irinotecan-hydrochloride0.7%6

Taken alongside

1
Levothyroxine-sodium2.1%18
2
Pantoprazole-sodium2.0%17
3
Acetaminophen1.9%16
4
Ergocalciferol1.5%13
5
Amlodipine1.2%10
6
Ondansetron1.2%10
7
Dexamethasone1.2%10
8
Oxycodone1.1%9
9
Potassium-chloride0.9%8
10
Atenolol0.9%8
11
Aspirin0.8%7
12
Omeprazole0.8%7
13
Metoprolol0.8%7
14
Levetiracetam0.8%7
15
Alprazolam0.8%7

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports larotrectinib side effects

42.4% of larotrectinib adverse event reports involve female patients and 43.0% involve male patients. The largest age group is adult at 48%. These figures reflect who reports side effects, not underlying risk.

Sex

Female42.4%
Male43.0%
Unknown14.6%

Age group

< 26.2%
2–1110.3%
12–174.1%
18–6447.8%
65+31.7%

What is larotrectinib used for

Conditions and purposes for which patients were taking larotrectinib when the adverse event was reported.

Acinar Cell Carcinoma Of PancreasAcute Lymphocytic LeukaemiaAcute Myeloid LeukaemiaAdenocarcinoma Of Salivary GlandAdverse EventAnti-infective TherapyAstrocytomaAcinar Cell Carcinoma Of PancreasAcinic Cell Carcinoma Of Salivary GlandAcute Myeloid LeukaemiaAdenocarcinomaAdenocarcinoma Of ColonAdenocarcinoma Of Salivary GlandAdenocarcinoma PancreasAdenoid Cystic Carcinoma

Showing 15 of 245 indications

Larotrectinib brand names and reporting trend

Larotrectinib is sold under the brand name Vitrakvi.

Brand names

Vitrakvi325

Quarterly reports (2019–2025)

20192020202220242025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking larotrectinib with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications